XT
OCUL icon

XTX Topco’s Ocular Therapeutix OCUL Stock Holding History

XTX Topco’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$996K Sell
101,471
-293,713
-74% -$2.66M 0.01% 1790
2026
Q1 		$3.35M Buy
395,184
+346,111
+705% +$3.3M 0.06% 492
2025
Q4 		$596K Buy
49,073
+14,640
+43% +$178K 0.02% 1449
2025
Q3 		$403K Buy
+34,433
New +$412K 0.02% 1258
2025
Q2 		– Sell
-22,605
Closed -$166K – 2936
2025
Q1 		$166K Buy
22,605
+11,012
+95% +$84.6K 0.01% 1750
2024
Q4 		$99K Buy
+11,593
New +$113K 0.01% 1769
2024
Q1 		– Sell
-27,942
Closed -$125K – 2171
2023
Q4 		$125K Buy
+27,942
New +$82.6K 0.03% 1083
2023
Q1 		– Sell
-236,851
Closed -$666K – 1552
2022
Q4 		$666K Buy
236,851
+184,585
+353% +$611K 0.14% 190
2022
Q3 		$217K Buy
52,266
+29,698
+132% +$150K 0.05% 729
2022
Q2 		$91K Sell
22,568
-13,199
-37% -$49.9K 0.04% 664
2022
Q1 		$177K Buy
35,767
+23,582
+194% +$131K 0.08% 436
2021
Q4 		$85K Buy
+12,185
New +$94.6K 0.05% 490
2021
Q3 		– Sell
-23,121
Closed -$328K – 951
2021
Q2 		$328K Buy
+23,121
New +$351K 0.11% 328

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

XTX Topco's OCUL Position: Q2 2026 in Review

XTX Topco reduced its Ocular Therapeutix (OCUL) stake by 74% in Q2 2026, selling an estimated $2.66M and leaving 101,471 shares worth $996K. The position accounts for 0.01% of the portfolio, ranked #1790.

XTX Topco first reported a position in OCUL in Q2 2021 and has held it in 13 quarters since. The position peaked at $3.35M in Q1 2026. 263 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • XTX Topco held 101,471 shares of Ocular Therapeutix worth $996K as of Q2 2026.
  • XTX Topco sold 293,713 Ocular Therapeutix shares in Q2 2026, an estimated $2.66M.
  • Ocular Therapeutix made up 0.01% of XTX Topco's portfolio in Q2 2026, its #1790 holding.
  • XTX Topco first reported a position in Ocular Therapeutix in Q2 2021 and has held it in 13 quarters since.
  • XTX Topco's Ocular Therapeutix position peaked at $3.35M in Q1 2026.
  • 263 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.